Episode Summary
In this week’s episode, John reviews some pharma breakthroughs—along with one major setback—and discusses the bold statement by the Department of Justice (DOJ) regarding the Affordable Care Act (ACA).
Episode Notes
In this week’s episode, John reviews some pharma breakthroughs—along with one major setback—and discusses the bold statement by the Department of Justice (DOJ) regarding the Affordable Care Act (ACA).
Highlights include:
- The Department of Justice issued a letter stating that it agrees with a federal judge who struck down the entire ACA as unconstitutional.
- The FDA approved the first drug to treat postpartum depression: Sage Therapeutics’ Zulresso (brexanolone).
- Amarin Corp. presented updated results for its ongoing Vascepa (icosapent ethyl) clinical trial, REDUCE-IT, at the American College of Cardiology Annual Meeting.
- Biogen is scrapping its investigational treatment for Alzheimer’s disease, and is canceling its Phase III ENGAGE and EMERGE clinical trials.
About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.
CONNECT WITH US:
🌐 Follow Health Care Rounds on LinkedIn
🌐 Follow Darwin Research Group on LinkedIn
📺 Watch Health Care Rounds on YouTube
⚙️ Health Care Rounds is produced by Grippi Media
Recommended Next
Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.
